Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) Director Rahul D. Ballal sold 3,237 shares of the company's stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $19.08, for a total transaction of $61,761.96. Following the sale, the director now directly owns 22,341 shares in the company, valued at $426,266.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Enliven Therapeutics Stock Down 1.1 %
NASDAQ ELVN opened at $18.59 on Thursday. Enliven Therapeutics, Inc. has a 52 week low of $9.80 and a 52 week high of $23.98. The firm's 50-day simple moving average is $16.22 and its two-hundred day simple moving average is $13.91.
Institutional Investors Weigh In On Enliven Therapeutics
Several institutional investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Enliven Therapeutics by 9.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company's stock valued at $170,000 after purchasing an additional 1,029 shares during the last quarter. Deutsche Bank AG increased its position in shares of Enliven Therapeutics by 16.7% during the third quarter. Deutsche Bank AG now owns 10,890 shares of the company's stock valued at $149,000 after buying an additional 1,559 shares during the period. Legal & General Group Plc increased its position in shares of Enliven Therapeutics by 8.9% during the third quarter. Legal & General Group Plc now owns 19,665 shares of the company's stock valued at $269,000 after buying an additional 1,610 shares during the period. Tower Research Capital LLC TRC bought a new stake in shares of Enliven Therapeutics during the first quarter valued at about $36,000. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Enliven Therapeutics by 1.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 158,440 shares of the company's stock valued at $2,193,000 after buying an additional 1,809 shares during the period. 95.08% of the stock is owned by hedge funds and other institutional investors.
About Enliven Therapeutics
(
Get Free Report)
READ THIS – If You Missed Out On The AI Boom
From Banyan Hill Publishing | Ad
Adam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy.
Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”
Click on Adam's shiny forehead for more details.
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
